Meet the DCCPS New and Early Stage R01 Investigators

  • Kimberly Canter, Ph.D.
    Alfred I. duPont Hospital for Children
    Pediatric Psychologist and Psychosocial Researcher

    My interest in serving this population began in college, when a lightbulb went off during an introductory psychology class. I had planned to pursue a career in medicine but was much more interested in the opportunity to help patients and families cope and manage stressors. My personal and professional experiences with cancer have fueled my passion to provide high-quality, accessible psychosocial care to families as they navigate what is likely one of the worst times of their lives.
  • Norah L. Henry, M.D., Ph.D.
    University of Michigan - Ann Arbor
    Breast Oncologist and Clinical and Translational Researcher

    Every week in clinic I see the struggles that patients with breast cancer face trying to tolerate their life-saving cancer medications. This has inspired me to understand what underlies the difficulties with medication compliance, and to explore interventions to reduce these challenges. I strive to help people keep taking their medications while maintaining their quality of life.
  • Matthew C. Hocking, Ph.D.
    Children's Hospital of Philadelphia
    Pediatric Psychologist and Behavioral Scientist

    As a graduate student, I worked in a multidisciplinary clinic where I conducted psychological consultations for survivors of childhood cancer. The experience of meeting these youth who had been cured of their cancer but were experiencing significant health problems and developmental issues had a substantial impact on me. I became particularly fascinated by the effects of cancer treatments on the developing brain and the different problems that occur as a result.
  • Shivan J. Mehta, M.D., M.B.A., M.S.H.P.
    University of Pennsylvania
    Gastroenterologist and Health Care Delivery Scientist

    An important moment for my research interests was realizing the importance of co-creating health care delivery interventions with clinical and operational leaders while employing rigorous research methods such as prospective randomization in pragmatic trials. This process has identified delivery programs with high potential to improve outcomes while also creating generalizable knowledge that can advance the science of population-based cancer screening.
  • Kirk J. Wangensteen, M.D., Ph.D.
    University of Pennsylvania

    I am driven to link genes to associated functions in liver diseases and I hope to make discoveries that make positive impacts on patients.